Background: There are limited data concerning the incidence density (ID) of ATTRwt, AL and AA amyloidosis in the Argentinean population. Our aim was to estimate the ID of ATTRwt, AL and AA amyloidosis at the Hospital Italiano Medical Care Program in Buenos Aires, Argentina.
Methods: Population was all members of a hospital-based health maintenance organization who were affiliated since January 2006 to December 2014. Each person was followed contributing time at risk since January 2006 or enrollment date to the final date. Incident cases of amyloidosis were captured from the institutional registry of amyloidosis. Incidence rate was calculated with 95% confidence intervals.
Results: During the nine-year study period, there were 15 patients with ATTRwt, 12 with AL and 2 with AA amyloidosis for 1 105 152 person-years of follow-up. The crude ID of ATTRwt amyloidosis was 13.5 (95%CI 8.1-22.4), that of AL amyloidosis 11 (95%CI: 6-19) and that of AA amyloidosis 1.8 (95%CI: 0.5-7.2) per 1 000 000 person-years. The highest ID was found in men (31.7 for ATTRwt, 15.9 for AL and 2.27 for AA amyloidosis per 1 000 000 person-years). The ID adjusted to the population of the city of Buenos Aires was 6.46 (95%CI: 3.17-9.74) for ATTRwt, 6.13 (95%CI: 2.57-9.7) for AL and 1.21 (95%CI: 0.56 to 2.99) for AA amyloidosis.
Conclusions: This is the first paper to report the incidence density of ATTRwt, AL and AA amyloidosis in Latin America. Our results are consistent with other studies from other regions. Although systemic amyloidosis is a rare disease, it is a major health problem because of its morbi-mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13506129.2016.1207626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amyloidosis and Heart Transplantation in a New Era.
Clin Transplant
January 2025
Department of Cardiovascular Medicine, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
Background: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.
Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.
Methods: This is a retrospective review of end-stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020.
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis.
Amyloid
December 2024
Department of Cardiology, German Heart Centre Munich, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Background: Wild-type transthyretin cardiac amyloidosis (ATTRwt) is an infiltrative disease leading to restrictive cardiomyopathy. We aimed to characterise exercise capacity in ATTRwt and to identify predictors of cardiopulmonary fitness, focusing on echocardiographic and clinical parameters.
Methods: We studied 110 ATTRwt patients from a prospective single-centre registry (2020-2024) by cardiopulmonary exercise testing (CPET).
Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis.
ESC Heart Fail
December 2024
Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Article Synopsis
- The study analyzed changes in electrocardiographic (ECG) characteristics in patients with different types of cardiac amyloidosis (AL, ATTRv, and ATTRwt) and looked at their predictive value for patient outcomes.
- In a large sample of 356 patients, it was found that those with ATTRwt had more conduction issues, while AL patients exhibited more signs of low QRS voltage and T wave inversion.
- Overall, the ECG abnormalities progressed similarly in all subtypes, but a longer QRS duration at baseline was associated with worse survival, indicating it could be a potential marker for advanced disease.
The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild-type transthyretin amyloidosis.
ESC Heart Fail
December 2024
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Article Synopsis
- The study aimed to evaluate the effects of trimetazidine, an antianginal medication, on heart function in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt).
- Twenty-two participants were enrolled in a randomized, double-blind trial, comparing the effects of trimetazidine to a placebo over four weeks, measuring various cardiovascular and mitochondrial functions.
- The results showed no significant improvements in key cardiac measures, such as pulmonary artery wedge pressure or mitochondrial function, indicating that trimetazidine did not provide benefits to patients with ATTRwt compared to the placebo.
Effect of tafamidis therapy on physical function in patients with wild-type transthyretin cardiac amyloidosis.
J Cardiol
November 2024
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Background: Tafamidis is used as disease-modifying treatment for patients with wild-type transthyretin cardiac amyloidosis (ATTRwt CA). However, the effects of tafamidis on exercise tolerance are unclear.
Methods: This single-center, prospective, observational study aimed to assess the effect of tafamidis on exercise tolerance in 36 patients with ATTRwt CA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!